MINI ORALS 2025
Bladder & Urothelial Cancer
Abstract Code: IUC24403-78
Relative Dose Intensity of Neoadjuvant Chemotherapy Predicts Pathological Response and Survival in Muscle-Invasive Urothelial Cancer: A Multicenter Retrospective Study
Abstract Code: IUC24392-85
Real-world use of erdafitinib in urothelial carcinoma: an Italian multicenter retrospective study
Abstract Code: IUC24432-80
Neoadjuvant or Induction Chemotherapy (N/IC) for Bladder Cancer: Updated “Real-World” Experience from Croatia
Abstract Code: IUC24412-78
The Safety and Efficacy of a Modified Di Stasi Regime for Patients with Non-Muscle Invasive Bladder Cancer During Times of Bacillus Calmette-Guérin Shortage
Abstract Code: IUC24409-84
Evaluation of a Transurethral Laser Ablation (TULA) Service for Superficial Bladder Cancer Management in an Outpatient Setting in a UK District General Hospital
Abstract Code: IUC24408-83
Outcomes of Distal ureterectomy with Boari flap reconstruction for ureteric Transitional cell carcinoma.
Precision Uro-Oncology
Abstract Code: IUC24390-83
Morphology of Circulating Tumor Cells: how it might relate to biology and clinics in prostate cancer
Abstract Code: IUC24420-77
Prognostic impact of ABCA1/ABCG1 expression, lipid parameters, and nephrectomy in patients with renal cell carcinoma receiving immune checkpoint inhibitors.
Abstract Code: IUC24411-77
In Search of Metastasis-Initiating Cells in Prostate Cancer
Abstract Code: IUC24418-84
Biomarkers detecting Minimal Residual Disease for predicting Risk of Relapse in Operable Urothelial Cancer: A Systematic Review and Meta-Analysis of Phase II/III Clinical Trials
Abstract Code: IUC22021-72
The INSIDE Study: Innovative Preclinical Models for Precision Medicine in Advanced Prostate Cancer
Abstract Code: IUC24431-79
Prognostic Role of Luminal and Basal Subtypes in Metastatic Prostate Cancer: A Retrospective Study
Abstract Code: IUC24410-76
Early PSA suppression with adjuvant abiraterone in high-risk prostate cancer: real-world data on the achievement of ultralow PSA levels
Prostate Cancer
Abstract Code: IUC24025-78
Early results of moderate hypofractionated radiotherapy implementation for localized prostate cancer patients in Vietnam.
Abstract Code: IUC24402-77
Preliminary results of 177Lu-PSMA-617 priming with Enzalutamide in Metastatic Castration-resistant Prostate Cancer: A Single-arm Phase 2 trial (Lu-PRIME)
Abstract Code: IUC24433-81
Docetaxel versus olaparib plus abiraterone as first-line treatment in patients with mCRPC: a retrospective single-centre analysis
Abstract Code: IUC24397-90
Short-term continence outcomes in men over 75 undergoing robotic-assisted radical prostatectomy
Abstract Code: IUC24406-81
ARTA-ATTACK Study: Assessment of Sarcopenia, Frailty, and Neurocognitive Impairment in Patients with Prostate Cancer Treated with Androgen Receptor-Targeted Agents: A Prospective Multicentre Observational Cohort Study
Supportive Care & Quality of Life
Abstract Code: IUC24422-79
Patient Satisfaction with Penile Prosthesis Insertion following Radical Pelvic Uro-Oncological Therapy
Diagnostics & Imaging in Uro-Oncology
Abstract Code: IUC24425-82
Nanosensors for early stage detection of Circulating Tumour Cell biomarkers in Prostate Cancer Diagnosis: A Systematic Review of Published Evidence
Abstract Code: IUC24413-79
Comparative Performance of AI vs Radiologists in Pre-Biopsy mpMRI Prostate Cancer Diagnosis: A Systematic Review and Meta-Analysis of Multi-Centre, Multi-Vendor Studies
Abstract Code: IUC24430-78
Lesion-Level Meta-Diagnostic of Cognitive vs Fusion MRI-Targeted Biopsy in PCa: PRECISION-2 Insights
Abstract Code: IUC24426-83
Predictors of Cancer Detection on Local Anaesthetic Transperineal (LATP) Prostate Biopsy: A Single-Centre Analysis
Renal Cancer
Abstract Code: IUC24358-87
Prognostic assessment of the Meet-URO score compared with the IMDC score in Metastatic Renal Cell Carcinoma (mRCC) receiving 1st line systemic therapies (Meet-URO 33 study)
Abstract Code: IUC24360-80
Second-line therapies of Metastatic Renal Cell Carcinoma (mRCC) after 1st line immune-combinations (ICI-combos) (Meet-URO 33 study)
Abstract Code: IUC24394-87
Meet-URO score update in Metastatic Renal Cell Carcinoma receiving 1st line Immune-Combinations
Abstract Code: IUC22940-82
A 7-Year Review of Robot-Assisted vs Laparoscopic Radical Nephrectomy at a UK District General Hospital (2018–2024)
Testicular Cancer
Abstract Code: IUC24415-81
Clinical outcomes in stage I seminoma patients aged ≥ 45 years according to treatment modality